Feature | July 03, 2014

Mobile AUC App Update Encourages Appropriate Use of TEE, Contrast and Stress Imaging

July 3, 2014 — The American Society of Echocardiography Foundation (ASEF) launched the second version of its free mobile Echo AUC app at the ASE Silver Anniversary Scientific Sessions in Portland, Ore., last week. The app, made possible by a grant from the ABIM Foundation and supported by the Robert Wood Johnson Foundation, was designed by physicians to assist other healthcare practitioners to follow appropriate care guidelines when ordering cardiovascular imaging tests, as part of the Choosing Wisely initiative.

The original version of the app was launched in the fall of 2013, and included all 98 indications for transthoracic echocardiography (TTE) from the 2011 Appropriate Use Criteria (AUC) document. Version 2.0 adds the remaining 104 indications, which encompass three additional echo modalities: transesophageal echo (TEE), stress echo (SE) and contrast echo (CE). Plus, there are six new algorithms for stress echo that help guide physicians in additional detail to determine if stress echo is appropriate in various scenarios.

“Adding the indications for three new modalities, especially SE, is an extremely valuable and important update for the Echo AUC app,” said David Wiener, M.D., FASE, director of clinical operations at the Jefferson Heart Institute. “Stress echo tends to be ordered quite often by non-cardiologists, and there is a great need for education regarding appropriate ordering in this modality. Also, many clinicians underutilize contrast echocardiography for various reasons; the updated app reminds us that contrast should be used any time we cannot clearly see two or more contiguous LV segments.”

ASE supports the use of contrast to assist practitioners in reducing sub-optimal images that will ultimately reduce duplicative testing.

The latest version of the Echo AUC app also includes new "Five Things Physicians and Patients Should Question" lists developed by ASE and other participating specialty societies as part of the Choosing Wisely campaign. These lists are evidence-based recommendations that can be utilized to help make wise decisions about the most appropriate care based on a patient's individual situation.

For more information: www.asecho.org

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init